Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…Abstract Number: 1703 • 2017 ACR/ARHP Annual Meeting
A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor
Background/Purpose: Allogeneic STRO-3 immunoselected mesenchymal precursor cells (MPCs) derived from bone marrow of healthy donors are a potent, homogeneous cell population which can be activated…Abstract Number: 1704 • 2017 ACR/ARHP Annual Meeting
Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Background/Purpose: Patients with systemic sclerosis (SSc) often display Raynaud’s phenomenon, which causes digital skin ulcers. Since these ulcers are not associated with autoimmune factors, conventional…Abstract Number: 1705 • 2017 ACR/ARHP Annual Meeting
Inhibition of EZH2 Stops Fibrosis and Improves Angiogenesis in Scleroderma
Background/Purpose: Scleroderma (SSc) is a complex disease that involves activation of the immune system, vascular complications, and tissue fibrosis. Although the pathogenesis of this disease…Abstract Number: 1706 • 2017 ACR/ARHP Annual Meeting
Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis
Background/Purpose: Dipeptidyl-peptidase-4 (DPP4) has been reported to identify a dermal fibroblast lineage involved in scaring and its inhibition leads to reduced scar formation. Its role…Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…Abstract Number: 1708 • 2017 ACR/ARHP Annual Meeting
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a life-threatening complication in SSc. In recent years, distinct genomic and molecular subtypes in SSc-ILD were identified and molecular…Abstract Number: 1709 • 2017 ACR/ARHP Annual Meeting
Classical Monocytes in the Pathogenesis of Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: In light of heterogeneous clinical manifestations in systemic sclerosis (SSc), transcriptional analysis of fibrotic tissue and circulating leukocytes may illuminate conserved processes driving inflammation…Abstract Number: 1710 • 2017 ACR/ARHP Annual Meeting
Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells Enhances the Transition of Endothelial to Mesenchymal Cells (Endo-MT) Induced By TGFβ through Down-Regulating PI3/Akt Signaling Pathway By Targeting PIK3R2
Background/Purpose: The accumulation of myofibroblasts in fibrotic tissue plays an important role in the pathogenesis of scleroderma (SSc) fibrosis. Recent studies have shown that myofibroblasts…Abstract Number: 1711 • 2017 ACR/ARHP Annual Meeting
SIRT1 May Protect Against Systemic Sclerosis-Related Pulmonary Fibrosis By Decreasing Pro-Inflammatory and Pro-Fibrotic Processes
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Sirtuin1 (SIRT1) is a deacetylase with known anti-inflammatory and anti-fibrotic…Abstract Number: 1712 • 2017 ACR/ARHP Annual Meeting
Microbial and Metabolic MULTI-Omic Correlations in Systemic Sclerosis Patients
Background/Purpose: The gastro-intestinal tract (GIT) is frequently involved in Systemic sclerosis (SSc). Perturbation in the gut microbiota may affect the body well-being and function and…Abstract Number: 1713 • 2017 ACR/ARHP Annual Meeting
Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients
Background/Purpose: Scleroderma renal crisis (SRC), characterised by accelerated hypertension and acute kidney injury, is a life-threatening complication of systemic sclerosis (SSc). Most SSc cases have…Abstract Number: 1714 • 2017 ACR/ARHP Annual Meeting
Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis
Background/Purpose: Hedgehog acyltransferase (Hhat) catalyzes the attachment of the fatty acid palmitate onto Sonic Hedgehog (Shh), a modification essential for Shh signaling activity. Palmitoylation of…Abstract Number: 1715 • 2017 ACR/ARHP Annual Meeting
Mitochondrial DNA Mutations and Respiratory Chain Dysfunction in Lung Fibrosis of Systemic Sclerosis
Background/Purpose: Recent data have implemented reactive oxygen species (ROS) in the etiology of interstitial lung disease (ILD) in systemic sclerosis. Recent data from bleomycin mice…Abstract Number: 1716 • 2017 ACR/ARHP Annual Meeting
TGFβ-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling
Background/Purpose: Aberrant activation of profibrotic pathways is a key feature of systemic sclerosis (SSc). Extensive evidence characterizes TGFβ- and canonical WNT-signaling as key drivers of…
ACR Meeting Abstracts